Lacosamide Oral Solution Approved by the NMPA

Kangrong Pharmaceutical’s Lacosamide Oral Solution has recently received regulatory approval from the National Medical Products Administration (NMPA), with the drug approval number NMPA Approval No. H20256504. The product is available in a strength of 200 mL: 2g.

Lacosamide is an analogue of D-serine, an endogenous amino acid that acts as a modulator of NMDA receptors. In vitro electrophysiological studies have shown that lacosamide selectively enhances the slow inactivation of voltage-gated sodium channels (VGSCs), thereby stabilising hyperexcitable neuronal membranes.

Lacosamide Oral Solution is primarily indicated as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy aged 4 years and older.

First published: 6 January, 2026